Eli Lilly (LLY) PT Lowered to $78 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Eli Lilly (LLY) PT Raised to $82 at Credit Suisse
April 25, 2018 8:59 AM EDTCredit Suisse raised its price target on Eli Lilly (NYSE: LLY) to $82.00 (from $80.00) while maintaining a Underperform rating.
... MoreEli Lilly (LLY) PT Raised to $100 at Berenberg
April 25, 2018 6:06 AM EDTBerenberg raised its price target on Eli Lilly (NYSE: LLY) to $100.00 (from $99.00) while maintaining a Buy rating.
... MoreEli Lilly (LLY) PT Raised to $95 at Deutsche Bank
April 25, 2018 4:58 AM EDTDeutsche Bank raised its price target on Eli Lilly (NYSE: LLY) to $95.00 (from $94.00) while maintaining a Buy rating.
... MoreEli Lilly (LLY) PT Maintained at $95 at Cowen on 1Q18 Report; 'Top & Bottom Line Beat... FY18 Guidance Raised'
April 24, 2018 11:50 AM EDTCowen maintained its price target on Eli Lilly (NYSE: LLY) at $95.00 while maintaining a Outperform rating, following the company's first quarter earnings report.
Analyst Steve Scala notes an upbeat outlook on the shares, as LLY reported first quarter sales and earnings per share results above... More
Eli Lilly & Co. (LLY) Tops Q1 EPS by 21c, Raises FY EPS Guidance
April 24, 2018 6:27 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $1.34, $0.21 better than the analyst estimate of $1.13. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.49 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2018 EPS of $5.10-$5.20, versus the... More
